Cara Therapeutics, Inc., a CURE member biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, is sponsoring and participating in a lunch symposium titled, “Kappa: Myths / misconceptions, and moving beyond Mu,” at the 25th Annual Clinical Meeting of the American Academy of Pain Management.

Leading pain experts will discuss the evolving medical and regulatory climate around mu-opioids and how kappa agonists may become an important treatment option. Experts will also discuss the Phase 2 data from Cara’s clinical program of CR845, a peripherally acting kappa receptor agonist for acute pain, as well as the future of analgesia.